Published On: Mon, Sep 19th, 2016

Q4 2016 EPS Estimates for Vertex Pharmaceuticals Inc. (VRTX) Cut by Analyst

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) – Research analysts at Leerink Swann decreased their Q4 2016 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued on Friday. Leerink Swann analyst G. Porges now anticipates that the firm will earn $0.16 per share for the quarter, down from their prior forecast of $0.22. Leerink Swann has a “Buy” rating and a $112.00 price target on the stock. Leerink Swann also issued estimates for Vertex Pharmaceuticals’ FY2017 earnings at $1.95 EPS.
A number of other equities research analysts have also issued reports on VRTX. Piper Jaffray Cos. reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Saturday, June 18th. Vetr lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating and set a $94.38 price objective for the company. in a report on Tuesday, May 31st. Cowen and Company reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Thursday, July 28th. BMO Capital Markets reissued a “hold” rating and issued a $87.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday. Finally, Jefferies Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 31st. Eleven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $118.45.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 92.71 on Monday. The stock has a 50 day moving average of $98.19 and a 200 day moving average of $89.42. Vertex Pharmaceuticals has a 12-month low of $75.90 and a 12-month high of $136.97. The company’s market cap is $22.97 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/q4-2016-eps-estimates-for-vertex-pharmaceuticals-inc-vrtx-cut-by-analyst.html

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.21 by $0.03. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The business earned $431.61 million during the quarter, compared to analyst estimates of $428.08 million. During the same quarter in the previous year, the business posted ($0.54) EPS. The company’s quarterly revenue was up 159.9% compared to the same quarter last year.
A number of institutional investors have recently bought and sold shares of the stock. Citizens Financial Group Inc RI raised its position in Vertex Pharmaceuticals by 27.0% in the second quarter. Citizens Financial Group Inc RI now owns 1,189 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 253 shares during the period. Mycio Wealth Partners LLC raised its position in Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares during the period. Paradigm Asset Management Co. LLC raised its position in Vertex Pharmaceuticals by 20.7% in the second quarter. Paradigm Asset Management Co. LLC now owns 1,450 shares of the pharmaceutical company’s stock worth $125,000 after buying an additional 249 shares during the period. BlueMountain Capital Management LLC raised its position in Vertex Pharmaceuticals by 69.3% in the first quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company’s stock worth $148,000 after buying an additional 764 shares during the period. Finally, Checchi Capital Advisers LLC raised its position in Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock worth $152,000 after buying an additional 73 shares during the period. Hedge funds and other institutional investors own 96.26% of the company’s stock.
In related news, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $84.82, for a total value of $435,126.60. Following the transaction, the director now directly owns 273,355 shares in the company, valued at approximately $23,185,971.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $92.37, for a total transaction of $600,405.00. Following the completion of the transaction, the director now owns 274,725 shares in the company, valued at $25,376,348.25. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by insiders.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>